Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer

Hillel Yaffe Medical Center

Status: Unknown

Conditions: Ovarian Cancer

Treatments: Other: Saline solution; Biological: IGF1R antibody MK0646

Study type: Observational

Funder types: Other

Identifiers

NCT02711865

HYMC-54-15

Details and patient eligibility

About

The main goal of this study is to employ a novel proteomic approach to identify predictive tumor biomarkers that will increase the efficacy of insulin-like growth factor (IGF1R) targeted therapy in epithelial ovarian cancer. It is expected that these predictive biomarkers will be applied to increase the response rate in selected groups of patients.

Enrollment: 20 estimated patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with ovarian cancer

Exclusion criteria

• All others

Trial design

20 participants in 2 patient groups

MK-0646

Description:

Tumor specimens removed from 20 women with ovarian cancer are injected into 40 mice treated with the IGF1R antibody MK-0646. The drug will be administered twice weekly, via IP injection at a dose of 500 microgram per animal.

Treatment:

Biological: IGF1R antibody MK0646

Control

Description:

Tumor specimens removed from 20 women with ovarian cancer are injected into 40 mice who receive no other treatment.

Treatment:

Other: Saline solution